SWITZERLAND - NGN Capital leads EUR 10m series-C for Santhera

Santhera Pharmaceuticals has raised EUR 10m in a series-C financing round, with the option of calling another EUR 5m. The oversubscribed funding round was led by NGN Capital, one of Santhera's largest current shareholders. New investors to the round include NeoMed Management (Jersey), two equity funds managed by Schroder Investment Management SA (Luxembourg) and BioMedinvest (Switzerland). In addition, existing investors Carnegie Asset Management, GIMV, Dow Chemical, Clariden Biotechnology Fund, 3i and private investors supported the round.